Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Sign Up to like & getrecommendations! Published in 2020 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2020.107219
Abstract: BACKGROUND Iguratimod, a small molecular drug, has been proven to have effective bone protection for treatment of patients with bone loss-related diseases, such as rheumatoid arthritis (RA). However, the exact bone protective mechanism of iguratimod… read more here.
Keywords: bone; rankl tnf; bone loss; iguratimod ... See more keywords